Cureus 1(9):117 Helmstdter J, Keppeler K, Kster L, Mnzel T, Daiber A, Steven S (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefitsthe role of the GLP-1 receptor
Retatrutide : Early trials reported weight loss results up to ~ 24% over 48 weeks among the strongest yet observed in metabolic-medication research
Most insurers currently cover GLP-1s, but only for treating diabetes and certain cardiac conditions
In addition to providing coverage of these drugs for obesity, which would be a new indication in Medicare and in most states under Medicaid, these efforts will also allow beneficiaries in participating states and Part D plans to access GLP-1s for obesity at a lower out-of-pocket cost than if they were to purchase them with cash at the direct-to-consumer prices offered by the manufacturers
These medications work by mimicking the action of naturally occurring GLP-1, a hormone released by the intestine in response to food intake
Healing takes time